These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 35863299

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Silencing of the RNA-binding protein HuR attenuates hyperalgesia and motor disability in experimental autoimmune encephalomyelitis.
    Sanna MD, Quattrone A, Galeotti N.
    Neuropharmacology; 2017 Sep 01; 123():116-125. PubMed ID: 28599923
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, Adlard N.
    BMJ Open; 2017 Mar 10; 7(3):e013430. PubMed ID: 28283486
    [Abstract] [Full Text] [Related]

  • 27. Icariin ameliorates the progression of experimental autoimmune encephalomyelitis by down-regulating the major inflammatory signal pathways in a mouse relapse-remission model of multiple sclerosis.
    Cong H, Zhang M, Chang H, Du L, Zhang X, Yin L.
    Eur J Pharmacol; 2020 Oct 15; 885():173523. PubMed ID: 32871176
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
    Yoshida Y, Tsuji T, Fujita T, Kohno T.
    Biol Pharm Bull; 2011 Oct 15; 34(6):933-6. PubMed ID: 21628899
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis.
    Leva G, Klein C, Benyounes J, Hallé F, Bihel F, Collongues N, De Seze J, Mensah-Nyagan AG, Patte-Mensah C.
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec 15; 1863(12):3016-3027. PubMed ID: 28899788
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
    Bomprezzi R, Schaefer R, Reese V, Misra A, Vollmer TL, Kala M.
    Scand J Immunol; 2011 Sep 15; 74(3):219-226. PubMed ID: 21615449
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A, Hervás JV, Quirant-Sánchez B, Mansilla MJ, Grau-López L, Ramo-Tello C, Martínez-Cáceres EM.
    CNS Neurosci Ther; 2016 Jul 15; 22(7):584-92. PubMed ID: 27080413
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.